Author

Alessandro Armuzzi

HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS
HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS

Alessandro Armuzzi  et al.

THE SOLUTE CARRIER LC22A4/OCTN1AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE
THE SOLUTE CARRIER LC22A4/OCTN1AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE

Alessandro Armuzzi  et al.

HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY
HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY

Alessandro Armuzzi  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Alessandro Armuzzi  et al.

RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE

Alessandro Armuzzi  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Alessandro Armuzzi  et al.

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

Alessandro Armuzzi  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Alessandro Armuzzi  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Alessandro Armuzzi  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

Alessandro Armuzzi  et al.

NEUTROPHIL-ONLY HISTOLOGICAL ASSESSMENT OF ULCERATIVE COLITIS CORRELATES WITH ENDOSCOPIC ACTIVITY AND PREDICTS LONG-TERM OUTCOMES IN A MULTICENTER STUDY
NEUTROPHIL-ONLY HISTOLOGICAL ASSESSMENT OF ULCERATIVE COLITIS CORRELATES WITH ENDOSCOPIC ACTIVITY AND PREDICTS LONG-TERM OUTCOMES IN A MULTICENTER STUDY

Alessandro Armuzzi  et al.

REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Alessandro Armuzzi  et al.

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE
DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Alessandro Armuzzi  et al.

ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS
ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS

Alessandro Armuzzi  et al.

Item 41 - 54 / 54
1 2
3